Visual Abstract: Efficacy, Safety of Telaglenastat Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma

JAMA Oncology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, SEPTEMBER 1, 2022

Media advisory: The full study and commentary are linked to this news release. A visual abstract is below.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2022.3511?guestAccessKey=c6ad7a6b-caf2-411c-a706-d6e65b18d0c6&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090122

 

Visual Abstract

Authors: Nizar M. Tannir, M.D., of the University of Texas MD Anderson Cancer Center in Houston, is the corresponding author.

(doi:10.1001/jamaoncol.2022.3511)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.